Therapeutic monoclonal antibodies at phase 3 clinical study for management of Covid-19

The new coronavirus was firstly identified in the late December 2019 that causes severe respiratory and other organ complications in Covid-19 patients. Although many attempts have been employed to introduce and provide effective medications against this infection, there is still no definitive treatment for the infection. However some agents have shown promising effects in patients and some others are in preliminary or clinical studies. Monoclonal antibodies are of great interest in the treatment of Covid-19, but despite the fact that more than 120 clinical trials have been performed or are being completed; only tocilizumab has shown promising results and is sometimes used in therapeutic protocols. In this review, therapeutic monoclonal antibodies against Covid-19 that are currently in phase 3 or higher clinical trial have been discussed.